BiomX raises ~$7.5M in PIPE; reports positive Phase 1b/2a data for BX004 in CF

BiomX Inc.

Private placement of 30.6M shares at $0.245; gross proceeds ~$7.5M in two closings.
First closing of ~$1.5M (5.98M securities) imminent; second closing contingent on shareholder approval.
Part 1 Phase 1b/2a: BX004 reduced P. aeruginosa by -1.42 log10 CFU/g vs -0.28 placebo at Day 15.
No safety events or emerging resistance; phages detected in all treated patients during dosing.
Part 2 (24 patients) expected Q3 2023; proceeds to fund BX004 CF development and working capital.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BiomX Inc. entered into Securities Purchase Agreement with accredited and non-U.S. investors valued at approximately $7.5 million gross proceeds (effective 2023-02-22).

Action: entry
Agreement: equity purchase
Counterparty: accredited and non-U.S. investors
Value: approximately $7.5 million gross proceeds
Effective: 2023-02-22

Exact text from the filing

On February 22, 2023, BiomX Inc. (the “ Company ”) executed a definitive Securities Purchase Agreement (the “ SPA ”) with accredited and non-U.S. investors relating to a private placement (the “ Offering ”) of an aggregate of 30,608,163 shares of the Company’s common stock (“ Shares ”), including shares issuable upon the exercise of pre-funded warrants (“ Pre-Funded Warrants ”) to purchase additional shares of the Company’s common stock (each, a “ Security ” and collectively, the “ Securities ”), at a purchase price of $0.245 per Share and $0.244 per Pre-Funded Warrant.

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-013615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.